Hanmath J Neboori, MD

Articles by Hanmath J Neboori, MD

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

ByVivek N. Patel, MD,Felix M. Chinea, MD,Deukwoo Kwon, PhD,Gustavo Fernandez, MD,Hanmath J Neboori, MD,Michael A. Samuels, MD,Laura M. Freedman, MD,Nagy M. Elsayad,Donald Weed, MD,Elizabeth Franzmann, MD,Chukwuemeka V. Ikpeazu, MD, PhD,Matthew C. Abramowitz, MD

March 19th 2017

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Latest Updated Articles

Uptake of Nononcology Gene Therapy Remains Slow in Hematology
Published: August 16th 2024 | Updated: August 19th 2024
Phase 3 Trial Seeks to Continue Supporting Arsa-Cel Gene Therapy for MLD
Published: March 18th 2024 | Updated: June 3rd 2024
Rapcabtagene Autoleucel Shows Promise for DLBCL in Updated Phase 2 Data
Published: December 7th 2024 | Updated:
Aimee C. Talleur, MD, on Predicting Response and Toxicity to Cell Therapy
Published: December 12th 2022 | Updated:
RPE Cell Therapy Shows Improvements in Early GA With AMD
Published: July 14th 2024 | Updated:
Multi-Characteristic Opsin Gene Therapy for Retinitis Pigmentosa Improves Multiple Measures of Vision
Published: May 18th 2023 | Updated:

Hanmath J Neboori, MD

Articles by Hanmath J Neboori, MD

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

Latest Updated Articles

Trending on CGTlive®

Around the Helix: Cell and Gene Therapy Company Updates – September 3, 2025

Preclinical Evidence for PH1 Gene Therapy

VeonGen Snags FDA RMAT Designation for Stargardt Gene Therapy VG801